摘要
CDK8及其旁系同源CDK1、以及CCNC、MED12和MED13基因,是介导多种致癌通路和化疗引起肿瘤支持旁分泌网络的转录调节因子。我们以前的观察认为乳腺癌中CDK8、CDK19和CCNC RNA的表达与较短的无复发生存率(RFS)有关,现在我们通过免疫组化分析发现,相对于非恶性乳腺组织,CDK8/19蛋白在浸润性导管癌中过度表达。转录数据的Meta-分析表明,在乳腺癌的所有分子亚型中,较高的CDK8的表达与较低的RFS有关。这些相关性在这些接受全身辅助治疗的病人中更明显,这表明CDK8影响全身治疗的失败。同样的相关性还存在于CDK19、CCNC和MED13中。与此相反,MED12显示了与较高RFS的相反关联。乳腺癌样本中CDK8的的表达水平直接与MYC的表达相关,CDK19、CCNC和MED13同样如此,另外与MED12基因呈负相关性。突变型p53肿瘤中CDK8、CDK19和CCNC的表达迅速升高,MED12的表达由于突变型p53肿瘤而下降。基因扩增是乳腺癌CDK8、CDK19、CCNC和MED13基因突变中最常见的类型(其中9.7%已扩增为MED13),而MED12中点突变更常见。这些结果表明CDK8及其相互作用基因的表达对乳腺癌辅助治疗反应具有深远影响,与CDK8对化疗引起肿瘤支持旁分泌活动的作用相一致。
关键词: 乳腺癌,细胞周期依赖性蛋白激酶8,细胞周期依赖性蛋白激酶19,细胞周期蛋白C,RNA聚合酶Ⅱ转录调节物12,RNA聚合酶Ⅱ转录调节物13,微阵列数据挖掘,组织微阵列
图形摘要
Current Cancer Drug Targets
Title:Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
Volume: 15 Issue: 8
Author(s): Eugenia V. Broude, Balázs Gyorffy, Alexander A. Chumanevich, Mengqian Chen, Martina S. J. McDermott and Michael Shtutman, James F. Catroppo and Igor B. Roninson
Affiliation:
关键词: 乳腺癌,细胞周期依赖性蛋白激酶8,细胞周期依赖性蛋白激酶19,细胞周期蛋白C,RNA聚合酶Ⅱ转录调节物12,RNA聚合酶Ⅱ转录调节物13,微阵列数据挖掘,组织微阵列
摘要: CDK8 and its paralog CDK19, in complex with CCNC, MED12 and MED13, are transcriptional regulators that mediate several carcinogenic pathways and the chemotherapy-induced tumor-supporting paracrine network. Following up on our previous observation that CDK8, CDK19 and CCNC RNA expression is associated with shorter relapse-free survival (RFS) in breast cancer, we now found by immunohistochemical analysis that CDK8/19 protein is overexpressed in invasive ductal carcinomas relative to non-malignant mammary tissues. Meta-analysis of transcriptomic data revealed that higher CDK8 expression is associated with shorter RFS in all molecular subtypes of breast cancer. These correlations were much stronger in patients who underwent systemic adjuvant therapy, suggesting that CDK8 impacts the failure of systemic therapy. The same associations were found for CDK19, CCNC and MED13. In contrast, MED12 showed the opposite association with a longer RFS. The expression levels of CDK8 in breast cancer samples were directly correlated with the expression of MYC, as well as CDK19, CCNC and MED13 but inversely correlated with MED12. CDK8, CDK19 and CCNC expression was strongly increased and MED12 expression was decreased in tumors with mutant p53. Gene amplification is the most frequent type of genetic alterations of CDK8, CDK19, CCNC and MED13 in breast cancers (9.7% of which have amplified MED13), whereas point mutations are more common in MED12. These results suggest that the expression of CDK8 and its interactive genes has a profound impact on the response to adjuvant therapy in breast cancer in accordance with the role of CDK8 in chemotherapy-induced tumor-supporting paracrine activities.
Export Options
About this article
Cite this article as:
Eugenia V. Broude, Balázs Gyorffy, Alexander A. Chumanevich, Mengqian Chen, Martina S. J. McDermott and Michael Shtutman, James F. Catroppo and Igor B. Roninson , Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer, Current Cancer Drug Targets 2015; 15 (8) . https://dx.doi.org/10.2174/156800961508151001105814
DOI https://dx.doi.org/10.2174/156800961508151001105814 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets Synthesis and Preliminary Biological Evaluation of Estrone Dimers
Letters in Drug Design & Discovery Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening A Tropical Lichen, Dirinaria consimilis Selectively Induces Apoptosis in MCF-7 Cells through the Regulation of p53 and Caspase-Cascade Pathway
Anti-Cancer Agents in Medicinal Chemistry Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery The Other Side of the Opioid Story: Modulation of Cell Growth and Survival Signaling
Current Medicinal Chemistry Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis
Current Topics in Medicinal Chemistry Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Nanoparticle Engineering Enhances Anticancer Efficacy of Andrographolide in MCF-7 Cells and Mice Bearing EAC
Current Pharmaceutical Biotechnology Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals